These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

448 related articles for article (PubMed ID: 23317397)

  • 1. The role of fibrate treatment in dyslipidemia: an overview.
    Katsiki N; Nikolic D; Montalto G; Banach M; Mikhailidis DP; Rizzo M
    Curr Pharm Des; 2013; 19(17):3124-31. PubMed ID: 23317397
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Fibrates are an essential part of modern anti-dyslipidemic arsenal: spotlight on atherogenic dyslipidemia and residual risk reduction.
    Tenenbaum A; Fisman EZ
    Cardiovasc Diabetol; 2012 Oct; 11():125. PubMed ID: 23057687
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Balanced pan-PPAR activator bezafibrate in combination with statin: comprehensive lipids control and diabetes prevention?
    Tenenbaum A; Fisman EZ
    Cardiovasc Diabetol; 2012 Nov; 11():140. PubMed ID: 23150952
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fibrates in the management of atherogenic dyslipidemia.
    Okopień B; Buldak L; Bołdys A
    Expert Rev Cardiovasc Ther; 2017 Dec; 15(12):913-921. PubMed ID: 29183206
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy of fibrates for cardiovascular risk reduction in persons with atherogenic dyslipidemia: a meta-analysis.
    Lee M; Saver JL; Towfighi A; Chow J; Ovbiagele B
    Atherosclerosis; 2011 Aug; 217(2):492-8. PubMed ID: 21592479
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Fibrates in the light of large clinical trials].
    Krysiak R; Rudzki H; Handzlik-Orlik G; Gdula-Dymek A; Okopień B
    Pol Merkur Lekarski; 2015 Apr; 38(226):222-7. PubMed ID: 25938391
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Therapeutic targets in the treatment of dyslipidemia: HDL and non-HDL cholesterol].
    Brea Hernando ÁJ
    Clin Investig Arterioscler; 2014 Jul; 26 Suppl 1():3-6. PubMed ID: 25043539
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Management of dyslipidemias with fibrates, alone and in combination with statins: role of delayed-release fenofibric acid.
    Moutzouri E; Kei A; Elisaf MS; Milionis HJ
    Vasc Health Risk Manag; 2010 Aug; 6():525-39. PubMed ID: 20730069
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Optimal pharmacotherapy to combat the atherogenic lipid triad.
    Chapman MJ; Redfern JS; McGovern ME; Giral P
    Curr Opin Cardiol; 2011 Sep; 26(5):403-11. PubMed ID: 21730827
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Optimal management of combined dyslipidemia: what have we behind statins monotherapy?
    Tenenbaum A; Fisman EZ; Motro M; Adler Y
    Adv Cardiol; 2008; 45():127-153. PubMed ID: 18230960
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Beyond low-density lipoprotein: addressing the atherogenic lipid triad in type 2 diabetes mellitus and the metabolic syndrome.
    Nesto RW
    Am J Cardiovasc Drugs; 2005; 5(6):379-87. PubMed ID: 16259526
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Fibrates - the present state of art].
    Krysiak R; Rudzki H; Handzlik-Orlik G; Gdula-Dymek A; Okopień B
    Pol Merkur Lekarski; 2016 Jun; 40(240):341-4. PubMed ID: 27403898
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Fibrates therapy: Rational use fenofibrate 2016. Executive summary].
    Brea A; Millán J; Ascaso JF; Blasco M; Díaz A; González-Santos P; Hernández-Mijares A; Mantilla T; Pedro-Botet JC; Pintó X;
    Clin Investig Arterioscler; 2016; 28(6):295-301. PubMed ID: 27609708
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Diabetic dyslipidaemia and the atherosclerosis].
    Márk L; Dani G
    Orv Hetil; 2016 May; 157(19):746-52. PubMed ID: 27133274
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Benefits and risks of the treatment with fibrates--a comprehensive summary.
    Okopień B; Bułdak Ł; Bołdys A
    Expert Rev Clin Pharmacol; 2018 Nov; 11(11):1099-1112. PubMed ID: 30328735
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Do persons with diabetes benefit from combination statin and fibrate therapy?
    Rosenblit PD
    Curr Cardiol Rep; 2012 Feb; 14(1):112-24. PubMed ID: 22213157
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fibrates Revisited: Potential Role in Cardiovascular Risk Reduction.
    Kim NH; Kim SG
    Diabetes Metab J; 2020 Apr; 44(2):213-221. PubMed ID: 32347023
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effect of fibrates on lowering low-density lipoprotein cholesterol and cardiovascular risk reduction: a systemic review and meta-analysis.
    Kim KA; Kim NJ; Choo EH
    Eur J Prev Cardiol; 2024 Feb; 31(3):291-301. PubMed ID: 37855457
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fibrates in 2003: therapeutic action in atherogenic dyslipidaemia and future perspectives.
    Chapman MJ
    Atherosclerosis; 2003 Nov; 171(1):1-13. PubMed ID: 14642400
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacological Targeting of the Atherogenic Dyslipidemia Complex: The Next Frontier in CVD Prevention Beyond Lowering LDL Cholesterol.
    Xiao C; Dash S; Morgantini C; Hegele RA; Lewis GF
    Diabetes; 2016 Jul; 65(7):1767-78. PubMed ID: 27329952
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.